Engineered T cells for cancer therapy. - Wikidata - awgldk - TriplyDB

Engineered T cells for cancer therapy.

Engineered T cells for cancer therapy.

http://www.wikidata.org/entity/Q34080368

about

Identifying Individual T Cell Receptors of Optimal Avidity for Tumor Antigens Synthetic biology for pharmaceutical drug discovery Adoptive T-cell therapy for cancer: The era of engineered T cells Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia The biorepository portal toolkit: an honest brokered, modular service oriented software tool set for biospecimen-driven translational research IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice.Strategies to genetically engineer T cells for cancer immunotherapy.Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy.Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer.Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies.IL-12 conditioning improves retrovirally mediated transduction efficiency of CD8+ T cells Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy.Rationale for combining immunotherapy with chemotherapy.Mammalian synthetic biology: emerging medical applications.CAR T-cell therapy: toxicity and the relevance of preclinical models.Anti-CD19 chimeric antigen receptor-modified T cells for B-cell malignancies: a systematic review of efficacy and safety in clinical trials.The immune system and cancer evasion strategies: therapeutic concepts.CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia.Melanoma Immunotherapy in Mice Using Genetically Engineered Pluripotent Stem Cells.Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You.Adoptive immunotherapy for the treatment of glioblastoma: progress and possibilities.RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma.Time to Akt: Superior tumor-reactive T cells for adoptive immunotherapy Single-cell multiplexed cytokine profiling of CD19 CAR-T cells reveals a diverse landscape of polyfunctional antigen-specific response.Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells.Current Status of Gene Engineering Cell Therapeutics.IL-2 and Beyond in Cancer Immunotherapy.Clinical grade manufacturing of genetically modified, CAR-expressing NK-92 cells for the treatment of ErbB2-positive malignancies.CAR T-cell therapy: opportunities and challenges.Redirected T cells in cancer therapy.Characterization of Postinfusion Phenotypic Differences in Fresh Versus Cryopreserved TCR Engineered Adoptive Cell Therapy Products.Combining a chimeric antigen receptor and a conventional T-cell receptor to generate T cells expressing two additional receptors (TETARs) for a multi-hit immunotherapy of melanoma.Novel T-cell-based vaccines via arming polyclonal CD4+ T cells with antigen-specific exosomes.Engineering nanoparticles to overcome barriers to immunotherapy.Ribosome display and selection of single-chain variable fragments effectively inhibit growth and progression of microspheres in vitro and in vivo.Novel EXO-T vaccine using polyclonal CD4 T cells armed with HER2-specific exosomes for HER2-positive breast cancer Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL

P2860

Q26774669-9DCAC585-71B8-4187-BBB7-C59BA69E2914 Q26775582-40A11CBE-9957-49DE-BB81-6582B6649C31 Q26800611-7800E99E-A6CE-4FB5-B188-115547BCDB37 Q26992272-DB7D1CD4-FB74-4D48-A6AD-5A9DAC0DA92D Q28084879-B41E188F-900A-49D8-B8AD-0D16A7C6D404 Q28387672-D7C3F38D-CC93-47BB-A918-DA4E0A480206 Q30355682-D05AED13-8A25-42B8-8D16-030665777AE0 Q33655849-7F96D735-8AE4-41C0-897D-F586E1400912 Q33851168-F68D5455-80C9-487E-9CF0-4D2CBCA231D2 Q36471557-1AC60285-88B6-4D49-B19E-6539EF9808D7 Q36551673-819923D2-DEE6-42B1-9A1F-5387D57A06F6 Q36727794-627F99D5-BD12-410C-B23A-AAF76D2215FE Q36884399-6E4EBB56-D77A-4CAA-8D19-57B933804A4E Q37517482-C8B0390F-EEE0-417F-A8BE-4A22DEE9EF62 Q37555940-95075C73-DF4B-4D61-BD5B-40D2F9C2B28F Q38389326-2855B845-136A-461D-A4DE-90AD5CFD1D94 Q38390803-966CF90A-A412-442C-97A6-22D208980BCF Q38525018-86794C88-1051-4A1F-AA7A-680EA7D1E959 Q38538645-6717E70F-5278-4B3D-B2A1-85BE9D83B661 Q38691172-36550D0A-4697-4AA3-B381-8F3151A7FDF1 Q38758807-26E305DC-1133-45BA-8F45-02D97D501102 Q38802594-99BF24EC-37AA-4ECF-AA71-E82C2BF57D05 Q38913549-749AB878-E406-488D-BC3B-C3D1B4747276 Q39045586-CE99C5ED-093E-447F-AFF3-E9F249759650 Q41450925-C3541E1C-C3B5-4860-97AB-D9391DF98850 Q41592770-C847633E-9BC6-4F60-B317-8FB52A2801AC Q45849227-730634A8-29CF-40C9-B482-F9100408D444 Q47625086-2438440D-05C0-4E07-8E70-EB6A3AB85E45 Q49829282-FD19F6A8-0DB7-418B-9B1E-C6CBE99B19FA Q50004232-F550B520-0896-4446-9C7D-EA78627E6951 Q50027343-E6881AFD-11A3-402A-B096-3CB6609FA9C6 Q50043438-86C562C2-EF5F-4996-AF4B-EDE4AB96FF7C Q50044514-FE23EF3B-5A93-4787-81E0-C4F77C00DDF8 Q50535275-56606FCF-B50E-48A0-B208-B1492B4A0A2E Q52859139-3BC22D54-D91B-4158-BD26-A08B4C8FCD38 Q53623298-658BD578-153A-4DA4-B6FA-F4CA8A087F88 Q54991276-6DA186CF-1BCC-45AB-96B0-229C8C8A1285 Q55330637-679F1B2F-03C4-42A7-91C2-1A204794488F Q58547842-E7C7108F-1536-4F27-8E7D-618A19E7C2D5 Q58714103-F18CD14E-F635-4669-B499-750B1A51AEA8

P2860

Engineered T cells for cancer therapy.

http://www.wikidata.org/entity/Q34080368

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Engineered T cells for cancer therapy.

@ast

Engineered T cells for cancer therapy.

@en

Engineered T cells for cancer therapy.

@nl

type

label

Engineered T cells for cancer therapy.

@ast

Engineered T cells for cancer therapy.

@en

Engineered T cells for cancer therapy.

@nl

prefLabel

Engineered T cells for cancer therapy.

@ast

Engineered T cells for cancer therapy.

@en

Engineered T cells for cancer therapy.

@nl

P1433

Q34080368-A7C823FD-9B02-4C26-BE94-D3B107EDFFEC

P1476

Q34080368-C8558FEF-8B3E-49C2-9CF4-F5A1D8F08970

P2093

Q34080368-8112A5B6-3A5C-4767-BF91-0C9ECF2EAE51

Q34080368-89C3FD7D-736F-4B70-8D7F-830207F12B42

Q34080368-B524A139-22F6-464C-BFA5-2014A3F23C8B

Q34080368-CB78FE81-E8B6-40D4-837B-52B1D333E99A

Q34080368-DB5CBE14-CBD2-45F9-86BB-0FBDD129D53F

Q34080368-E216AE7B-BBC7-4D25-83F1-73C9646177A9

Q34080368-FCC7A3DD-8DC9-4502-9474-B89228317906

P2860

Q34080368-0BC31441-04B4-4BA3-A24D-24092231B161

Q34080368-1AB9234F-CF9F-4D96-95A0-41D839CF8408

Q34080368-1D990704-9123-4B38-AFFF-A74B1D7B69A0

Q34080368-272A960B-5256-4DA8-843D-AA37282238F2

Q34080368-29289474-134D-472C-8194-09954818D370

Q34080368-32D31CDB-04CF-4CBB-9D99-0A6D7BE0EC0A

Q34080368-418E751C-BF17-4BD4-8815-A86A20BEF00A

Q34080368-44C50F11-9311-4181-B7E0-8AEDE1B61528

Q34080368-48DD597D-B851-4A55-BF13-69493FEE4480

Q34080368-4D552988-9064-4BDF-8243-592FCC1587DE

P2888

Q34080368-F90EFC1E-64BC-4DD1-B403-7942807CB855

P304

Q34080368-8B6E97B1-2556-47A7-862D-C54C250D1337

P31

Q34080368-0287E63F-7B05-48E1-BB05-33435C12D42D

P356

Q34080368-BE2F90BC-FB31-44F1-BED1-C3D32988367F

P433

Q34080368-ED1FA710-A250-4F26-ACC0-B81E7E29C011

P478

Q34080368-49A5937E-A0A6-4D2E-B956-AC7AE2FF0291

P50

Q34080368-275F90A9-BC79-49AE-B2A2-91C7D8347B81

P577

Q34080368-3472B2A7-01D7-4959-B8CC-56C8A999C948

P5875

Q34080368-0F80FB46-DCEA-4DCC-8E3C-E38738A3C4E7

P6179

Q34080368-3A89BCC4-C73E-4C58-9D15-4C6D78CAAB0E

P698

Q34080368-3ACDCBC7-3FA0-4AE4-992F-104CD25B7CFC

P932

Q34080368-5A1448D2-F3CB-4A8A-86B6-CB39D7742214

P356

S00262-014-1568-1

P1433

Cancer Immunology, Immunotherapy

P1476

Engineered T cells for cancer therapy.

@en

P2093

Bruce L Levine

http://www.w3.org/2001/XMLSchema#string

Carl H June

http://www.w3.org/2001/XMLSchema#string

David L Porter

http://www.w3.org/2001/XMLSchema#string

Gabriela Plesa

http://www.w3.org/2001/XMLSchema#string

Laura A Johnson

http://www.w3.org/2001/XMLSchema#string

Stephan A Grupp

http://www.w3.org/2001/XMLSchema#string

Yangbing Zhao

http://www.w3.org/2001/XMLSchema#string

P2860

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

Cancer regression in patients after transfer of genetically engineered lymphocytes

Chimeric antigen receptor therapy for cancer

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1

Cancer/testis antigens, gametogenesis and cancer

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

P2888

s00262-014-1568-1

P304

969-975

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00262-014-1568-1

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

63

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-06-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263295082

http://www.w3.org/2001/XMLSchema#string

P6179

1037895949

http://www.w3.org/2001/XMLSchema#string

P698

24943274

http://www.w3.org/2001/XMLSchema#string

P932

4142345

http://www.w3.org/2001/XMLSchema#string